In April 2020 during the SARS-CoV-2 outbreak UK pediatricians alerted the National Health Service of a new systemic<unk>  condition similar to Kawasaki disease in<unk>  testing positive for the virus
Cases were then reported worldwide with patients admitted to ICUs in the USA4,5,10, Canada10Italy11, and UK2,3
Thought to be an immunologically mediated<unk>  syndrome associated with previous SARS-CoV-2 infection1
Cases occur 3-5.5 weeks after patients tested positive for SARS-CoV-2
While Kawasaki disease has a predilection for<unk>  of Asian descent, MIS-C seems to affect African American<unk>  more often9
Compared to Kawasaki patients are generally older (median age 8.6 vs 2.5)1 and had a predominance of GI symptoms
Patients with MIS-C are significantly more likely to present with dyspnea, vomiting, diarrhea, lymphopenia, and elevated LDH and and D-dimer compared to patients with COVID-19 without MIS-C 6
Cases occur 3-5.5 weeks after patients tested positive for SARS-CoV-2
Compared to Kawasaki patients are generally older (median age 8.6 vs 2.5)1 and had a predominance of GI symptoms
Occurs in 2/100,000 persons under 214
In a systematic review published June 2020, 11/7780 (0.14%) COVID-19 positive<unk>  met the CDC’s criteria for MIS-C6
Multisystem inflammatory syndrome in children
SARS-CoV-2
Seizures in patients with HIV-AIDS
Kawasaki disease
High altitude pharyngitis and bronchitis
Toxic shock syndrome
Pediatric fever of uncertain source
Juvenile idiopathic arthritis